Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-s4m2s Total loading time: 0.28 Render date: 2021-10-24T15:08:12.824Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes

Published online by Cambridge University Press:  22 April 2020

Giovanni Tafuri*
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Chantal Bélorgey
Affiliation:
Haute Autorité de Santé (HAS), 5 Avenue du Stade de France, 93210Saint-Denis, France
Carlo Favaretti
Affiliation:
European Public Health Association (EUPHA), Otterstraat 118, 3513CRUtrecht, The Netherlands Centre on Leadership in Medicine, Catholic University of the Sacred Heart, Largo F. Vito 1, 00168Rome, Italy
Edith Frénoy
Affiliation:
European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône, 1050Ixelles, Belgium
Flora Giorgio
Affiliation:
European Commission, Directorate General for Health and Food Safety, Rue Breydel 4, 1000Brussels, Belgium
Marcus Guardian
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Ansgar Hebborn
Affiliation:
F. Hoffmann-La Roche AG, Pharmaceutical Division, Basel, Switzerland
François Houÿez
Affiliation:
European Organisation for Rare Diseases (Eurordis), 96 rue Didot, 75014Paris, France
Jessica Imbert
Affiliation:
MedTech Europe, Rue Joseph II 40, 1000Brussels, Belgium
Denis Lacombe
Affiliation:
European Organisation for Research and Treatment of Cancer (EORTC), Avenue E. Mounier 83, 1200Brussels, Belgium
Jordi Llinares Garcia
Affiliation:
European Medicines Agency (EMA), Domenico Scarlattilaan 6, 1083HNAmsterdam, The Netherlands
Zoe Garrett
Affiliation:
National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Elena Petelos
Affiliation:
European Public Health Association (EUPHA), Otterstraat 118, 3513CRUtrecht, The Netherlands European Forum for Primary Care (EFPC), Otterstraat 118, 3513CRUtrecht, The Netherlands Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Voutes University Campus, 70013HeraklionCrete, Greece Health Services Research Department, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Minderbroedersberg 4-6, 6211 LKMaastricht, The Netherlands
Ingvil Saeterdal
Affiliation:
Norwegian Institute of Public Health (NIPH), PO Box 222 Skøyen, 0213Oslo, Norway
Ad Schuurman
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Anna Lefevre Skjöldebrand
Affiliation:
Swedish Medtech, Sveavägen 63, 113 59Stockholm, Sweden
Valentina Strammiello
Affiliation:
European Patients' Forum (EPF), Chaussée d'Etterbeek 180, 1040Etterbeek, Belgium
Daniel Widmer
Affiliation:
European Union of General Practitioners (UEMO), Rue des Deux Églises 37-39, 1000Brussels, Belgium
Anne Willemsen
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Niklas Hedberg
Affiliation:
Tandvårds & Läkemedelsförmånsverket (TLV), Fleminggatan 18, 112 26Stockholm, Sweden
*
Author for correspondence: Giovanni Tafuri, E-mail: gtafuri@zinl.nl; Admin_EUNETHTA@zinl.nl

Abstract

The European Network for Health Technology Assessment (EUnetHTA) organizes an annual Forum with stakeholders to receive feedback on its activities, processes, and outputs produced. The fourth edition of the EUnetHTA Forum brought together representatives of HTA bodies, patient organizations, healthcare professionals (HCPs), academia, payers, regulators, and industry. The aim of this paper is to provide an overview of the highlights presented at the 2019 EUnetHTA Forum, reporting the main items and themes discussed in the plenary panel and breakout sessions. The leading topic was the concept of unmet medical need seen from different stakeholders' perspectives. Breakout sessions covered the joint production of assessment reports and engagement with payers, patients, and HCPs. Synergies, pragmatism, and inclusiveness across Member States and stakeholders were emphasized as leading factors to put in place a collaboration that serves the interest of patients and public health in a truly European spirit.

Type
Article Commentary
Copyright
Copyright © Cambridge University Press 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

EURODIS. Breaking the Access Deadlock to Leave No One Behind. A contribution by EURORDIS and its Members on possibilities for patients' full and equitable access to rare disease therapies in Europe. 2018. Available from: http://download2.eurordis.org.s3.amazonaws.com/positionpapers/eurordis_access_position_paper_final_4122017.pdf.Google Scholar
Proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU [refd 2019 Dec 3]. Available from: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51final_en.pdf.Google Scholar
European Medicines Agency. PRIME: priority medicines [refd 2019 Dec 3]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines.Google Scholar
Ministère des Solidarités et de la Santé. Le forfait innovation [refd 2019 Dec 3]. Available from: https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/recherche-et-innovation/forfait-innovation.Google Scholar
United Nations. Sustainable development goals [refd 2020 Jan 28]. Available from: https://sustainabledevelopment.un.org/sdg3.Google Scholar
World Health Organization. Ensure healthy lives and promote wellbeing for all at all ages (Sub-goal of 3.8 of SDG3) [refd 2019 Dec 3]. Available from: https://www.who.int/sdg/targets/en/.Google Scholar
European Network for Health Technology Assessment. Topic Identification, Selection and Prioritisation (TISP) [refd 2019 Dec 3]. Available from: https://eunethta.eu/services/horizon-scanning/.Google Scholar
European Network for Health Technology Assessment. EUnetHTA Procedure Guidance for handling the Declaration of Interest [refd 2019 Dec 3]. Available from: https://eunethta.eu/doi/.Google Scholar
European Network for Health Technology Assessment. Patient Input in Relative Effectiveness Assessments [refd 2019 Dec 3]. Available from: https://eunethta.eu/wp-content/uploads/2019/06/Final_290519_Patient-Input-in-REAs.pdf.Google Scholar
Pontes, C, Zara, C, Torrent-Farnell, J, Obach, M, Nadal, C, Vella-Bonanno, P, et al. Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab. Appl Health Econ Health Policy. 2020;18:516.CrossRefGoogle ScholarPubMed
Ermisch, M, Bucsics, A, Vella Bonanno, P, Arickx, F, Bybau A payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.CrossRefGoogle Scholar
Vella Bonanno, P, Ermisch, M, Godman, B, Martin, AP, Van Den Bergh, J, Bezmelnitsyna, L, et al. Adaptive pathways: Possible next steps for payers in preparation for their potential implementation. Front Pharmacol. 2017;8:497.CrossRefGoogle Scholar
European Medicines Agency. EMA-EUnetHTA three-year work plan [refd 2019 Dec 3]. Available from: https://www.ema.europa.eu/en/documents/other/ema-eunethta-three-year-work-plan-2017-2020_en.pdf.Google Scholar
Vreman, RA, Heikkinen, I, Schuurman, A, Sapede, C, Garcia, JL, Hedberg, N, et al. Unmet medical need: an introduction to definitions and stakeholder perceptions. Value Health. 2019;22:1275–128.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Tafuri et al. supplementary material

Tafuri et al. supplementary material

Download Tafuri et al. supplementary material(PDF)
PDF 191 KB
1
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *